ADVANCED THERAPY IN PATIENTS WITH PRIMARY AND POSTPOLYCYTHEMIC MYELOFIBROSIS

Ph-negative myeloproliferative neoplasm are the group of hematologic disorders which includes primary myelofibrosis, polycythemia vera, essential trombocytemia and several rare diseases. After the discovery of V617 Fgain-of-function mutation the new period of diagnostics, treatment and evaluating of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	A. N. Alekseeva, O. E. Ochirova, L. B. Sodnomova, E. B. Zhalsanova
Formato:	article
Lenguaje:	RU
Publicado:	Scientific Сentre for Family Health and Human Reproduction Problems 2017
Materias:	primary myelofibrosis jak-2 xmpn target therapy Science Q
Acceso en línea:	https://doaj.org/article/a4815a4296a44801ba5a931e35d897bd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a4815a4296a44801ba5a931e35d897bd
record_format	dspace
spelling	oai:doaj.org-article:a4815a4296a44801ba5a931e35d897bd2021-11-23T06:14:38ZADVANCED THERAPY IN PATIENTS WITH PRIMARY AND POSTPOLYCYTHEMIC MYELOFIBROSIS2541-94202587-959610.12737/article_59fad511cd4e68.37206651https://doaj.org/article/a4815a4296a44801ba5a931e35d897bd2017-07-01T00:00:00Zhttps://www.actabiomedica.ru/jour/article/view/409https://doaj.org/toc/2541-9420https://doaj.org/toc/2587-9596Ph-negative myeloproliferative neoplasm are the group of hematologic disorders which includes primary myelofibrosis, polycythemia vera, essential trombocytemia and several rare diseases. After the discovery of V617 Fgain-of-function mutation the new period of diagnostics, treatment and evaluating of MPN prognosis began. At the current moment several molecules inhibiting JAK2 function are developed. Advanced therapy in patients with primary and post-polycythemic myelofibrosis included molecules inhibiting JAK2 function resulted in rapid and durable improvements in splenomegaly and disease-related symptoms in the phase 3 trials COMFORT-I and COMFORT-II. The effectiveness of the advanced therapy included molecule inhibiting JAK2 was evaluated in three patients with primary myelofibrosis and post-polycitemic myelofibrosis. All represented clinical cases demonstrated positive dynamics of the disease manifested in spleen size reduction, improvement of the symptoms and in one case in reduction of blood transfusions. None of three patients met serious adverse events leading to dose reduction or discontinuation of the molecule inhibiting JAK2. Target agents therapy demonstrated high treatment rates in patients with primary and post-polycythemic myelofibrosis. Thus, it is clearly necessary to perform molecular diagnosis, screening tests at early stages of the chronic myeloproliferative disease for the selection of patients in need for specific treatment.A. N. AlekseevaO. E. OchirovaL. B. SodnomovaE. B. ZhalsanovaScientific Сentre for Family Health and Human Reproduction Problemsarticleprimary myelofibrosisjak-2xmpntarget therapyScienceQRUActa Biomedica Scientifica, Vol 2, Iss 4, Pp 39-42 (2017)
institution	DOAJ
collection	DOAJ
language	RU
topic	primary myelofibrosis jak-2 xmpn target therapy Science Q
spellingShingle	primary myelofibrosis jak-2 xmpn target therapy Science Q A. N. Alekseeva O. E. Ochirova L. B. Sodnomova E. B. Zhalsanova ADVANCED THERAPY IN PATIENTS WITH PRIMARY AND POSTPOLYCYTHEMIC MYELOFIBROSIS
description	Ph-negative myeloproliferative neoplasm are the group of hematologic disorders which includes primary myelofibrosis, polycythemia vera, essential trombocytemia and several rare diseases. After the discovery of V617 Fgain-of-function mutation the new period of diagnostics, treatment and evaluating of MPN prognosis began. At the current moment several molecules inhibiting JAK2 function are developed. Advanced therapy in patients with primary and post-polycythemic myelofibrosis included molecules inhibiting JAK2 function resulted in rapid and durable improvements in splenomegaly and disease-related symptoms in the phase 3 trials COMFORT-I and COMFORT-II. The effectiveness of the advanced therapy included molecule inhibiting JAK2 was evaluated in three patients with primary myelofibrosis and post-polycitemic myelofibrosis. All represented clinical cases demonstrated positive dynamics of the disease manifested in spleen size reduction, improvement of the symptoms and in one case in reduction of blood transfusions. None of three patients met serious adverse events leading to dose reduction or discontinuation of the molecule inhibiting JAK2. Target agents therapy demonstrated high treatment rates in patients with primary and post-polycythemic myelofibrosis. Thus, it is clearly necessary to perform molecular diagnosis, screening tests at early stages of the chronic myeloproliferative disease for the selection of patients in need for specific treatment.
format	article
author	A. N. Alekseeva O. E. Ochirova L. B. Sodnomova E. B. Zhalsanova
author_facet	A. N. Alekseeva O. E. Ochirova L. B. Sodnomova E. B. Zhalsanova
author_sort	A. N. Alekseeva
title	ADVANCED THERAPY IN PATIENTS WITH PRIMARY AND POSTPOLYCYTHEMIC MYELOFIBROSIS
title_short	ADVANCED THERAPY IN PATIENTS WITH PRIMARY AND POSTPOLYCYTHEMIC MYELOFIBROSIS
title_full	ADVANCED THERAPY IN PATIENTS WITH PRIMARY AND POSTPOLYCYTHEMIC MYELOFIBROSIS
title_fullStr	ADVANCED THERAPY IN PATIENTS WITH PRIMARY AND POSTPOLYCYTHEMIC MYELOFIBROSIS
title_full_unstemmed	ADVANCED THERAPY IN PATIENTS WITH PRIMARY AND POSTPOLYCYTHEMIC MYELOFIBROSIS
title_sort	advanced therapy in patients with primary and postpolycythemic myelofibrosis
publisher	Scientific Сentre for Family Health and Human Reproduction Problems
publishDate	2017
url	https://doaj.org/article/a4815a4296a44801ba5a931e35d897bd
work_keys_str_mv	AT analekseeva advancedtherapyinpatientswithprimaryandpostpolycythemicmyelofibrosis AT oeochirova advancedtherapyinpatientswithprimaryandpostpolycythemicmyelofibrosis AT lbsodnomova advancedtherapyinpatientswithprimaryandpostpolycythemicmyelofibrosis AT ebzhalsanova advancedtherapyinpatientswithprimaryandpostpolycythemicmyelofibrosis
_version_	1718417025347354624

ADVANCED THERAPY IN PATIENTS WITH PRIMARY AND POSTPOLYCYTHEMIC MYELOFIBROSIS

Ejemplares similares